4-AcO-DET

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-07srcOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
5. 2026-09-07srcReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
6. 2026-09-07srcCorrelation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
7. 2026-09-07srcNovel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders
8. 2026-09-07srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
9. 2026-09-07srcStructure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
10. 2026-09-07srcReceptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
11. 2026-09-07srcMarked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study
12. 2026-09-07srcAbuse liability profile of three substituted tryptamines
13. 2026-09-07srcPharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and SERT
14. 2026-09-07srcAvoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors
15. 2026-09-07srcBeyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action
16. 2026-09-07srcPeakAL: Protons I Have Known and Loved, Too - Another Fifty Shades of Grey-Market Spectra. Supplementary Data
17. 2026-09-07srcRecreational use, analysis and toxicity of tryptamines.
18. 2026-09-07srcLower-Dose Psycholytic Therapy - A Neglected Approach
19. 2026-09-07srcToxicology and Analysis of Psychoactive Tryptamines.
20. 2026-09-07srcPharmacokinetics of Psilocybin: A Systematic Review
21. 2026-09-07srcDifferential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
22. 2026-09-07src4-AcO-DET (Ethacetin) compound record
23. 2026-09-07src4-AcO-DET/Ethacetin Degradation (Erowid)
24. 2026-09-07src4-Acetoxy-DET (Ethacetin) - Wikidoc
25. 2026-09-07src4-HO-DET (CZ-74) — DMT-Nexus Wiki
26. 2026-09-07srcSchedules of Controlled Substances: Proposed Placement of 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT in Schedule I
27. 2026-09-07srcHanscarl Leuner: Pioneer of Hallucinogen Research and Psycholytic Therapy
28. 2026-09-07srcDEA Scheduling: PMA as Schedule I hallucinogen (38 FR 26447, July 2, 1973)
29. 2026-09-04issueIssued emergency
30. 2026-09-04issueIssued info_card
31. 2026-09-04issueIssued notice
32. 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
33. 2026-06-04publicationPublication — backfill
34. 2026-04-28revisionRevision 1
35. 2026-04-28absenceSearched ClinicalTrials.gov for "4-AcO-DET ethacetin" — no results
36. 2026-04-28absenceSearched PubMed for "4-AcO-DET ethacetin diethyltryptamine acetate pharmacology" — no results
37. 2026-04-28absenceSearched OpenAlex for "4-acetoxy-DET ethacetin tryptamine psychedelic" — no results
38. 2026-04-28genGeneration — pipeline-v5 · with 1 morepipeline-v5
39. 2026-04-28rungeneration run

The same entries, as forms: six forms.